Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation
Conditions
Interventions
Budesonide/Glycopyrronium/Formoterol Fumarate
Placebo
+1 more
Locations
7
Germany
Research Site
Ahrensburg, Germany
Research Site
Berlin, Germany
Research Site
Frankfurt, Germany
Research Site
Hanover, Germany
Research Site
Harefield, United Kingdom
Research Site
London, United Kingdom
Start Date
November 24, 2025
Primary Completion Date
May 31, 2027
Completion Date
May 31, 2027
Last Updated
April 15, 2026
NCT05746039
NCT07190209
NCT07307781
NCT07509606
NCT07451977
NCT07477600
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions